Annual Meeting Highlights

ASH 2016 Annual Meeting Highlights in Myelodysplastic Syndromes
ASH 2016 Annual Meeting Highlights in Myelodysplastic Syndromes
Guillermo Garcia-Manero, MD; Guillermo Montalb√°n Bravo, MD; Mikkael A. Sekeres, MD, MS; and David P. Steensma, MD, FACP
Release Date: January 11, 2017
Expiration Date: January 11, 2018
Health care providers, especially community-based practitioners, are challenged with attending major medical conferences, learning about new data, and understanding their relevance and potential impact on clinical practice. In this activity, participants will learn about key highlights of the most impactful and groundbreaking data in myelodysplastic syndromes (MDS), presented at the 2016 American Society of Hematology (ASH) annual meeting. Leading experts in the field of MDS will share their insights on a variety of abstracts, covering topics including, but not limited to, hypomethylating agents, immunomodulatory drugs, and new combination therapies.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
Begin, Earn CreditView Only, No Credit

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of

©2017 MediCom Worldwide, Inc. All rights reserved